document.writeln("\n \n \n \n \n \n \n \n \n
Mass High Tech Newspaper | Mass High Tech: The Journal of New England Technology | Life Sciences
Mass High Tech: The Journal of New England Technology : breaking news from Mass High Tech
MS experts join Biogen Idec R&D team\n - Cambridge biotechnology firm Biogen Idec Inc. has added multiple sclerosis experts John Richert and Nancy Richert to its research\n and development team.
Charles River revenue hit by downturn\n - Wilmington-based contract research organization Charles River Laboratories reported that sales dropped 5 percent for the fourth\n quarter of 2009, compared to the year-ago period. Revenue for the year was down slightly.
Nyer Medical delisting paves way for dissolution\n - Nyer Medical Group Inc., a Holliston-based holding company with medical supplies businesses, has announced plans to voluntarily\n de-list its securities from the Nasdaq Stock Market and to move forward with dissolving the company.
Cosmetic laser firm Cynosure plans cost cuts amid sales drop\n - Cynosure Inc., a developer of lasers used for cosmetic procedures and dermatology-related applications, said a rebound from\n its year-long sales slump is still a ways off, and it plans to cut its annual operating expenses by up to 12 percent to weather\n the storm.
Biogen\'s MS drug drives profits up in 2009\n - Biogen Idec is reporting that the company?s profits were up 24 percent for 2009, driven by revenue from its multiple sclerosis\n therapy, Tysabri.
\n
View all...
\n
\n \n \n \n \n \n \n \n \n
Slater puts $500K into wound startup CytoSolv\n - CytoSolv Inc., a biotech startup in Providence, R.I., has taken in $500,000 in seed-stage funding from the Slater Technology\n Fund, Rhode Island?s state-backed venture capital fund.
Yale researchers ID disease-treating proteins\n - Yale scientists have developed color-coded proteins, using a mutation-prone virus, that researchers can use to identify proteins\n to treat diseases.
Cara Therapeutics\' painkiller hits on positive results\n - Connecticut biotechnology firm Cara Therapeutics Inc. has received positive data from a Phase 2 clinical trial for its opioid\n painkiller, CR845. The trial evaluated the efficacy of CR845 for 46 women after laparoscopic-assisted hysterectomy.
Olympics to use Billerica firm?s medical device\n - Belmont Instrument Corp. has announced that the Olympic Organizing Committee asked the company to install its blood infusion\n product at the mobile hospital that will treat Olympic athletes at the Winter Games in Vancouver, Canada.
Alnylam takes step toward in vivo delivery patent\n - Cambridge-based Alnylam Pharmaceuticals Inc. has cleared a key hurdle in its bid for a patent covering small interfering RNAs\n (siRNAs) intended for in vivo delivery.
\n
");